Upcoming Dividend • May 22
Upcoming dividend of US$0.29 per share Eligible shareholders must have bought the stock before 29 May 2026. Payment date: 16 June 2026. The company is not currently making a profit and there are not enough cash flows to support it either. Trailing yield: 10%. Within top quartile of British dividend payers (5.7%). Higher than average of industry peers (2.2%). Reported Earnings • May 06
First quarter 2026 earnings released: US$2.81 loss per share (vs US$0.001 profit in 1Q 2025) First quarter 2026 results: US$2.81 loss per share (down from US$0.001 profit in 1Q 2025). Revenue: US$969.2m (down 7.2% from 1Q 2025). Net loss: US$389.9m (down US$390.0m from profit in 1Q 2025). Revenue is forecast to stay flat during the next 3 years compared to a 5.3% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 92 percentage points per year, which is a significant difference in performance. Declared Dividend • May 03
Fourth quarter dividend of US$0.29 announced Dividend of US$0.29 is the same as last year. Ex-date: 29th May 2026 Payment date: 16th June 2026 Dividend yield will be 9.8%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not covered by cash flows (107% cash payout ratio). The dividend has increased by an average of 8.8% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Duyuru • May 01
Perrigo Company plc announces Quarterly dividend, payable on June 16, 2026 Perrigo Company plc announced Quarterly dividend of USD 0.2900 per share payable on June 16, 2026, ex-date on May 29, 2026 and record date on May 29, 2026. Duyuru • Apr 22
Perrigo Company plc to Report Q1, 2026 Results on May 06, 2026 Perrigo Company plc announced that they will report Q1, 2026 results Pre-Market on May 06, 2026 Duyuru • Mar 23
Perrigo Company plc, Annual General Meeting, Apr 30, 2026 Perrigo Company plc, Annual General Meeting, Apr 30, 2026. Location: 25 north wall quay, dublin, d01 h104, ireland., United States New Risk • Feb 26
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. Cash payout ratio: 107% Dividend yield: 8.2% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Reported Earnings • Feb 26
Full year 2025 earnings released: US$10.13 loss per share (vs US$1.17 loss in FY 2024) Full year 2025 results: US$10.13 loss per share (further deteriorated from US$1.17 loss in FY 2024). Revenue: US$4.25b (down 2.8% from FY 2024). Net loss: US$1.40b (loss widened US$1.24b from FY 2024). Revenue is forecast to stay flat during the next 3 years compared to a 5.1% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 68 percentage points per year, which is a significant difference in performance. Duyuru • Feb 26
Perrigo Company plc Provides Earnings Targets for the Fiscal Year 2026 Perrigo Company plc provided earnings targets for the fiscal year 2026. For the year, the company total net sales outlook of -5.5% to -1.5%, versus the prior year. Declared Dividend • Feb 21
Third quarter dividend of US$0.29 announced Dividend of US$0.29 is the same as last year. Ex-date: 2nd March 2026 Payment date: 24th March 2026 Dividend yield will be 7.9%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (61% cash payout ratio). The dividend has increased by an average of 8.8% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Duyuru • Feb 20
Perrigo Announces Quarterly Dividend, Payable on March 24, 2026 Perrigo Company plc announced that its Board of Directors has approved a quarterly dividend of $0.29 per share, or $1.16 per share on an annualized basis. The cash dividend is payable on March 24, 2026, to shareholders of record on March 2, 2026. Duyuru • Feb 13
Perrigo Company plc to Report Q4, 2025 Results on Feb 26, 2026 Perrigo Company plc announced that they will report Q4, 2025 results Pre-Market on Feb 26, 2026 Upcoming Dividend • Nov 21
Upcoming dividend of US$0.29 per share Eligible shareholders must have bought the stock before 28 November 2025. Payment date: 16 December 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 9.5%. Within top quartile of British dividend payers (5.7%). Higher than average of industry peers (2.2%). Duyuru • Nov 18
Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit on Behalf of Perrigo Company plc Shareholders Glancy Prongay & Murray LLP (GPM), announced that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captioned French v. Perrigo Company plc, et al., Case No. 1:25-cv-09596, on behalf of persons and entities that purchased or otherwise acquired Perrigo Company plc (Perrigo or the Company) securities between February 27, 2023 and November 4, 2025, inclusive (the Class Period). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act). Investors are hereby notified that they have 60 days from the date of this notice to move the Court to serve as lead plaintiff in this action. The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the infant formula business acquired from Nestlé suffered from significant underinvestment in maintenance, operational improvements, and repairs; (2) that Perrigo needed to make substantial capital and operational expenditures above the Company’s outwardly stated cost estimates to remediate the infant formula business; (3) that there were significant manufacturing deficiencies in the facility for the Company’s infant formula business; (4) that, as a result of the foregoing, the Company’s financial results, including earnings and cash flow, were overstated; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Reported Earnings • Nov 06
Third quarter 2025 earnings released: EPS: US$0.092 (vs US$0.13 loss in 3Q 2024) Third quarter 2025 results: EPS: US$0.092 (up from US$0.13 loss in 3Q 2024). Revenue: US$1.04b (down 4.1% from 3Q 2024). Net income: US$12.7m (up US$30.3m from 3Q 2024). Profit margin: 1.2% (up from net loss in 3Q 2024). Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Duyuru • Nov 05
Perrigo Company plc Updates Earnings Guidance for the Full Year of 2025 Perrigo Company plc updated earnings guidance for the full year of 2025. For the year, the company now expects net sales growth to be between negative 2.5% to negative 3.0% due primarily to infant formula industry dynamics and soft OTC consumption trends. Declared Dividend • Nov 03
Second quarter dividend of US$0.29 announced Shareholders will receive a dividend of US$0.29. Ex-date: 28th November 2025 Payment date: 16th December 2025 Dividend yield will be 5.5%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (65% cash payout ratio). The dividend has increased by an average of 8.8% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Duyuru • Oct 29
Perrigo Company plc Declares Quarterly Dividend, Payable on December 16, 2025 Perrigo Company plc announced that its Board of Directors declared a quarterly dividend of $0.290 per share, payable on December 16, 2025, to shareholders of record on November 28, 2025. Duyuru • Oct 22
Perrigo Company plc to Report Q3, 2025 Results on Nov 05, 2025 Perrigo Company plc announced that they will report Q3, 2025 results on Nov 05, 2025 Upcoming Dividend • Aug 22
Upcoming dividend of US$0.29 per share Eligible shareholders must have bought the stock before 29 August 2025. Payment date: 16 September 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 5.0%. Lower than top quartile of British dividend payers (5.5%). Higher than average of industry peers (2.4%). Reported Earnings • Aug 07
Second quarter 2025 earnings released: US$0.004 loss per share (vs US$0.77 loss in 2Q 2024) Second quarter 2025 results: US$0.004 loss per share (improved from US$0.77 loss in 2Q 2024). Revenue: US$1.06b (flat on 2Q 2024). Net loss: US$500.0k (loss narrowed 100% from 2Q 2024). Profit margin: 0% (up from net loss in 2Q 2024). Revenue is forecast to grow 2.3% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings. Duyuru • Aug 06
Perrigo Company plc Reaffirms Earnings Guidance for the Fiscal Year 2025 Perrigo Company plc reaffirmed earnings guidance for the fiscal year 2025. For the period, Company expects Reported net sales growth of 0% to 3%. Organic net sales growth of 1.5% to 4.5%. Declared Dividend • Aug 04
First quarter dividend of US$0.29 announced Shareholders will receive a dividend of US$0.29. Ex-date: 29th August 2025 Payment date: 16th September 2025 Dividend yield will be 4.3%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not adequately covered by cash flows (93% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Duyuru • Jul 31
Perrigo Company plc Declares Quarterly Dividend, Payable on September 16, 2025 Perrigo Company plc announced that its Board of Directors declared a quarterly dividend of $0.290 per share, payable on September 16, 2025, to shareholders of record on August 29, 2025. Duyuru • Jul 23
Perrigo Company plc to Report Q2, 2025 Results on Aug 06, 2025 Perrigo Company plc announced that they will report Q2, 2025 results on Aug 06, 2025 Duyuru • Jul 15
KKR & Co. Inc. (NYSE:KKR) entered into a Master Sale and Purchase Agreement to acquire Aco Hud Nordic AB and Assets related to Dermacosmetics Business of Perrigo Company plc, Perrigo Pharma Holding Nederland BV, and Perrigo Holding NV for approximately €330 million. KKR & Co. Inc. (NYSE:KKR) entered into a Master Sale and Purchase Agreement to acquire Aco Hud Nordic AB and Assets related to Dermacosmetics Business of Perrigo Company plc, Perrigo Pharma Holding Nederland BV, and Perrigo Holding NV for approximately €330 million on July 13, 2025. Under the terms of the transaction, KKR & Co. Inc will pay €210 million for the shares of Aco Hud Nordic AB and €90 million for the assets to be acquired, subject to customary adjustments for inventory, working capital, debt and cash. Additionally, KKR & Co. Inc. will pay an earnout payment of up to €27 million cash in relation to the financial performance of the ACO Brand and the Biodermal Brand in the financial years 2025, 2026, and 2027. In case of termination of transaction, KKR & Co. Inc. will pay a termination fee of €15 million.
For the period ending December 31, 2024, Aco Hud Nordic AB and the Assets related to Dermacosmetics Business of Perrigo Company plc reported total revenue of €125 million.
The transaction is subject to the satisfaction or waiver of customary closing conditions, including, among others: (1) receipt of regulatory approvals in certain jurisdictions, (2) consummation of pre-closing restructuring transactions with respect to the Target, (3) completion of works council consultation procedures in certain countries and (4) the closing of KKR’s previously announced proposed acquisition of Karo Healthcare. The expected completion of the transaction is in the first quarter of 2026. Expected net proceeds from the transaction would be directed towards previously announced capital allocation priorities, including further strengthening the Perrigo Company’s balance sheet and supporting long-term value creation.
Latham & Watkins LLP acted as legal advisor for Perrigo Company. Alvaro Membrillera, Anna Van de moortel, Ian Barratt, Natasha Smith, and Brett Ackerman of Kirkland & Ellis acted as legal advisor for KKR & Co. Inc. Greenhill & Co., Inc. acted as financial advisor for Perrigo Company. Duyuru • Jul 02
Perrigo Company plc Announces Executive Changes Perrigo Company plc announced that to support this alignment, including category strategy execution, go-to-market excellence and global demand generation across all regions, Roberto Khoury has been appointed EVP and Chief Commercial Officer. Mr. Khoury has a strong track record of success leading Perrigo's CSCI business and will play a key role in aligning commercial functions with the new global category model. Mr. Khoury will assume responsibility for operating results in both CSCI and CSCA and will partner closely with David Ball, EVP and Chief Brand and Digital Officer, who is responsible for global category leadership. As part of this alignment, the roles of EVP and President CSCI and EVP and President CSCA will be discontinued. Triona Schmelter will depart the organization and be available on a consultative basis until October 31, 2025. Perrigo extends its sincere gratitude for her leadership and contributions over the past two years, including the launch of Opill which was a significant inflection point for CSCA and women's reproductive health in the U.S. Duyuru • Jun 05
Perrigo Company plc Announces Executive Changes Perrigo Company plc announced the appointment of Matt Winterman as Executive Vice President, Product Supply, Operations Strategy and Transformation Officer, effective June 23, 2025. Mr. Winterman succeeds Ron Janish, who will retire from the Company on September 30, 2025, following a distinguished career at Perrigo spanning more than two decades. Throughout his tenure, Mr. Janish played an integral role in advancing and aligning the Company's supply chain with its transformation to a consumer self-care leader and steering its Supply Chain Reinvention program, which significantly reduced portfolio complexity and improved forecast accuracy. Mr. Winterman brings more than 20 years of global supply chain and strategy leadership to Perrigo. Most recently, he served as SVP of Global Supply Chain and Strategy at AstraZeneca, overseeing a $54 billion supply chain across 5,000 SKUs. He also served as Global Head of end-to-end Supply Chain at Roche Holding AG, and prior to that in roles of increasing responsibility for technical operations strategy and supply chain performance at GSK plc. Mr. Winterman graduated with a Bachelor of Science degree in Economics from the University of Bristol. Board Change • Jun 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Kevin Egan was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Upcoming Dividend • May 23
Upcoming dividend of US$0.29 per share Eligible shareholders must have bought the stock before 30 May 2025. Payment date: 17 June 2025. The company is not currently making a profit and its cash payout ratio is 93%. Trailing yield: 4.4%. Lower than top quartile of British dividend payers (5.7%). Higher than average of industry peers (2.6%). Reported Earnings • May 07
First quarter 2025 earnings released: EPS: US$0.001 (vs US$0.03 in 1Q 2024) First quarter 2025 results: EPS: US$0.001 (down from US$0.03 in 1Q 2024). Revenue: US$1.04b (down 3.5% from 1Q 2024). Net income: US$100.0k (down 98% from 1Q 2024). Profit margin: 0% (down from 0.4% in 1Q 2024). Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 8% per year and the company’s share price has also fallen by 8% per year. Declared Dividend • May 04
Fourth quarter dividend of US$0.29 announced Shareholders will receive a dividend of US$0.29. Ex-date: 30th May 2025 Payment date: 17th June 2025 Dividend yield will be 4.4%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (64% cash payout ratio). The dividend has increased by an average of 10% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Duyuru • Apr 30
Perrigo Company plc Announces Quarterly Dividend, Payable on June 17, 2025 Perrigo Company plc announced that its Board of Directors declared a quarterly dividend of $0.290 per share, payable on June 17, 2025, to shareholders of record on May 30, 2025. Duyuru • Apr 24
Perrigo Company plc to Report Q1, 2025 Results on May 07, 2025 Perrigo Company plc announced that they will report Q1, 2025 results on May 07, 2025 Duyuru • Mar 12
Perrigo Company plc, Annual General Meeting, May 01, 2025 Perrigo Company plc, Annual General Meeting, May 01, 2025. Location: 70 sir john rogerson`s quay, grand canal dock, d02 r296, dublin 2 Ireland Duyuru • Feb 28
Perrigo Company plc Provides Earnings Targets for the Fiscal Year 2025 Perrigo Company plc provided earnings targets for the fiscal year 2025. For the year, the company targets all-in net sales growth to be between 1% to 3%. Organic net sales growth to be between 2.5% to 4.5%. Reported Earnings • Feb 28
Full year 2024 earnings released: US$1.17 loss per share (vs US$0.033 loss in FY 2023) Full year 2024 results: US$1.17 loss per share (further deteriorated from US$0.033 loss in FY 2023). Revenue: US$4.37b (down 6.1% from FY 2023). Net loss: US$160.7m (loss widened US$156.3m from FY 2023). Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Declared Dividend • Feb 22
Third quarter dividend increased to US$0.29 Dividend of US$0.29 is 5.1% higher than last year. Ex-date: 7th March 2025 Payment date: 25th March 2025 Dividend yield will be 4.4%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not adequately covered by cash flows (96% cash payout ratio). The dividend has increased by an average of 10% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Duyuru • Feb 20
Perrigo Company plc Increases Its Quarterly Dividend, Payable on March 25, 2025 Perrigo Company plc announced that its Board of Directors has approved a 5% increase in the Company's quarterly dividend to $0.290 per share, or $1.16 per share on an annual basis, up from $0.276 per share. This marks the 22nd consecutive year Perrigo has increased its dividend. The cash dividend is payable on March 25, 2025, to shareholders of record on March 7, 2025. Duyuru • Jan 31
Perrigo Company plc to Report Q4, 2024 Results on Feb 27, 2025 Perrigo Company plc announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Feb 27, 2025 Duyuru • Jan 17
Perrigo Company plc Appoints Jonas Samuelson to as A Member of Board of Directors and Audit Committee and the Nominating and Governance Committee On January 15, 2025, the Board of Directors of Perrigo Company plc appointed Jonas Samuelson to serve as a member of the Company’s board of directors effective as of January 15, 2025. Mr. Samuelson will also serve on the Audit Committee and the Nominating and Governance Committee of the Board. Mr. Samuelson brings substantial CEO, CFO and Board experience from both public and private companies. Most recently, he served as President, CEO and board member of AB Electrolux, where he also previously served as CFO for the Electrolux Group. Additionally, Mr. Samuelson served as CFO and Executive Vice President for Munters AB and held leadership roles in commercial finance, treasury and business planning and analysis with General Motors and Saab Automobile AB. Duyuru • Jan 06
Perrigo Company plc Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer Perrigo Company plc announced the expansion of its Chief Scientific Office by uniting and integrating all global quality, pharmacovigilance, patient safety, regulatory affairs and innovation teams, enhancing organizational agility and scale. This expansion also further supports the Company's consumer-led innovation pipeline. To lead this expanded office, the Company has appointed Abbie Lennox as Executive Vice President and Chief Scientific Officer. Ms. Lennox is an experienced consumer self-care leader with a successful track record of driving regulatory excellence, product life cycle management and new product innovation across well-known consumer self-care portfolios. Ms. Lennox joins Perrigo from Bayer where she served as Executive Board Member and Chief Trust and Science Officer, responsible for leading the regulatory, medical affairs, safety and quality teams. She led multiple innovation launches – both product and claim-based – across global product categories, including cardio, digestive health, allergy, cough, cold, pain, dermatology, women's health, VMS (Vitamins, Minerals and Supplements) and Rx-to-OTC switches. Specifically, Ms. Lennox provided scientific leadership for the U.S. Rx-to-OTC switch for Astepro, emphasizing consumer-centric claims supported by robust medical insights. She also led the introduction of Rennie Gum, the first European OTC chewing gum for digestive health, by navigating rigorous clinical and registration requirements while prioritizing consumer experience. Prior to her time at Bayer, she served in regulatory affairs leadership roles with Reckitt Benckiser, where she advanced their regulatory approach to pipeline delivery across multiple health and wellness brands. Ms. Lennox holds a First Class BSc (Honors) degree in Biomedical Science and Chemistry from De Montfort University. Alison Ives, who previously served as Chief Scientific Officer, has been appointed to lead a newly formed Disruptive Growth Team focused on identifying and pursuing emerging growth opportunities through category disruption and entering new markets. After successfully serving as Perrigo's Chief Scientific Officer, along with more than 20 years of experience in science-focused roles, Ms. Ives has deep expertise to unlock emerging growth opportunities. Recent Insider Transactions • Dec 11
Independent Director recently sold US$497k worth of stock On the 9th of December, Jeffrey Kindler sold around 18k shares on-market at roughly US$28.27 per share. This transaction amounted to 76% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$1.5m more than they bought in the last 12 months. Upcoming Dividend • Nov 25
Upcoming dividend of US$0.28 per share Eligible shareholders must have bought the stock before 29 November 2024. Payment date: 17 December 2024. The company is not currently making a profit and its cash payout ratio is 96%. Trailing yield: 3.9%. Lower than top quartile of British dividend payers (5.9%). Higher than average of industry peers (2.5%). Declared Dividend • Nov 11
Third quarter dividend of US$0.28 announced Shareholders will receive a dividend of US$0.28. Ex-date: 29th November 2024 Payment date: 17th December 2024 Dividend yield will be 4.2%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not adequately covered by cash flows (96% cash payout ratio). The dividend has increased by an average of 10% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Reported Earnings • Nov 07
Third quarter 2024 earnings released: US$0.13 loss per share (vs US$0.11 profit in 3Q 2023) Third quarter 2024 results: US$0.13 loss per share (down from US$0.11 profit in 3Q 2023). Revenue: US$1.09b (down 3.2% from 3Q 2023). Net loss: US$17.6m (down 214% from profit in 3Q 2023). Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Duyuru • Nov 07
Perrigo Company plc Provides Revenue Guidance for the Fiscal Year 2024 Perrigo Company plc provided revenue guidance for the fiscal year 2024. For the year, the company expects organic net sales and reported net sales outlooks towards the lower end of its previously stated ranges of organic net sales growth versus the prior year of -3% to -1% and reported net sales growth versus the prior year of -5% to -3%. The Company continues to expect gross and operating margin expansion compared to the prior year. Duyuru • Nov 02
Perrigo Company plc Announces Quarterly Dividend, Payable on December 17, 2024 Perrigo Company plc announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on December 17, 2024, to shareholders of record on November 29, 2024. Duyuru • Oct 23
Perrigo Company plc to Report Q3, 2024 Results on Nov 06, 2024 Perrigo Company plc announced that they will report Q3, 2024 results on Nov 06, 2024 Duyuru • Sep 04
Perrigo Company plc Appoints Charles Atkinson, as Executive Vice President, General Counsel and Secretary Perrigo Company plc announced the appointment of Charles Atkinson as Executive Vice President, General Counsel and Secretary. He is a skilled lawyer with nearly 25 years of experience, mostly within the regulated consumer self-care industry. Mr. Atkinson joins Perrigo after a successful career at Haleon plc and its prior parent, GSK plc, most recently serving as Interim General Counsel for Haleon. During his 20-plus year combined tenure at Haleon/GSK, Mr. Atkinson successfully advised across numerous transactions and integrations, including the creation of Haleon and subsequent separation from its parent shareholders GSK and Pfizer. He has also served as global head of corporate legal and was lead counsel for various parts of the self-care business, including supply chain, R&D and innovation, business development, and intellectual property. This included managing the lifecycle of regulated healthcare products, advising GSK's largest self-care business and providing counsel for product development, including leading the switch for Flonase® to over-the-counter status. He obtained his law degree from University College London. Todd Kingma, who came out of retirement to serve as Interim Executive Vice President, General Counsel & Secretary, will work with Mr. Atkinson through a transitionary period. Mr. Kingma's intimate knowledge of Perrigo and its global team will allow for a highly seamless transition. Upcoming Dividend • Aug 26
Upcoming dividend of US$0.28 per share Eligible shareholders must have bought the stock before 30 August 2024. Payment date: 17 September 2024. The company is not currently making a profit but it is cash flow positive. Trailing yield: 3.8%. Lower than top quartile of British dividend payers (5.5%). Higher than average of industry peers (2.1%). Recent Insider Transactions • Aug 23
Advisor recently sold US$969k worth of stock On the 20th of August, Svend Andersen sold around 35k shares on-market at roughly US$27.69 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought US$282k more than they sold in the last 12 months. Duyuru • Aug 19
Perrigo Company plc Appoints David Ball as Executive Vice President and Chief Brand and Digital Officer Perrigo Company plc announced the appointment of Dr. David Ball as Executive Vice President and Chief Brand and Digital Officer. In this newly created position, Dr. Ball will be responsible for an enterprise-wide marketing strategy that incorporates deep understanding of consumer needs and translates those into winning brand strategies, tactics, and actions. He will also evaluate untapped market opportunities and develop strategies to scale the Company's brand-building efforts. Dr. Ball brings over 15 years of global consumer goods experience, spanning various commercial roles, including brand management, marketing, innovation, and research and development. He joins Perrigo from Bayer Consumer Healthcare, where he served as General Manager and Vice President of Marketing for the Digestive Health business in North America, achieving record financial performance. He also played a key role in Bayer's acquisition of a direct-to-consumer healthcare technology company and helped establish a transformative "white space" incubator group. Prior to Bayer, Dr. Ball spent a decade at Procter and Gamble in leadership positions across multiple business units and functions. Dr. Ball holds a PhD in Biophysics and Genetics from Sheffield University in England, which adds a unique dimension to his consumer goods expertise. His scientific background, combined with his experience in biotechnology, provides a valuable perspective on innovation and sustainable practices. Declared Dividend • Aug 11
Second quarter dividend of US$0.28 announced Shareholders will receive a dividend of US$0.28. Ex-date: 30th August 2024 Payment date: 17th September 2024 Dividend yield will be 4.1%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (64% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Reported Earnings • Aug 03
Second quarter 2024 earnings released: US$0.77 loss per share (vs US$0.066 profit in 2Q 2023) Second quarter 2024 results: US$0.77 loss per share (down from US$0.066 profit in 2Q 2023). Revenue: US$1.07b (down 11% from 2Q 2023). Net loss: US$105.7m (down US$114.6m from profit in 2Q 2023). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Duyuru • Jul 20
Perrigo Company plc to Report Q2, 2024 Results on Aug 02, 2024 Perrigo Company plc announced that they will report Q2, 2024 results on Aug 02, 2024 Duyuru • Jul 11
Esteve Healthcare S.L. completed the acquisition of HRA Pharma Rare Diseases America, LLC from Perrigo Company plc. Esteve Healthcare S.L. signed a binding offer to acquire HRA Pharma Rare Diseases America, LLC from Perrigo Company plc (NYSE:PRGO) for approximately €280 million on April 24, 2024. Esteve Healthcare S.L. entered into a Purchase and Sale Agreement to acquire HRA Pharma Rare Diseases America, LLC from Perrigo Company plc on July 3, 2024. As reported, the total consideration of up to €275 million consists of an upfront cash payment of €190 million and up to €85 million in potential earnout payments based on the Rare Diseases business achieving certain sales milestones. Following the information and consultation process with HRA Pharma Works Council in France, Perrigo would be able to exercise the put option granted by ESTEVE and enter into a definitive agreement with ESTEVE for the sale of the Rare Diseases business. The transaction is subject to the satisfaction of the HRA Works Council consultation and customary closing conditions, including receipt of regulatory approvals and is expected to close during the third quarter of 2024. Morgan Stanley & Co. LLC is serving as financial advisor to Perrigo Company plc, and Igor Kirman, Esq., Victor Goldfeld, Esq., and Eric M. Feinstein, Esq. of Wachtell, Lipton, Rosen & Katz is serving as its legal counsel. Perella Weinberg Partners is serving as financial advisor to Esteve Healthcare, S.L. and Guillermo Guardia and Jose Maria Vilaseca of Clifford Chance, S.L.P. acted as its legal counsel.Esteve Healthcare S.L. completed the acquisition of HRA Pharma Rare Diseases America, LLC from Perrigo Company plc on July 10, 2024. In 2023, the HRA Pharma Rare Diseases business delivered net sales of approximately €50 million and adjusted EBITDA of approximately €20 million. Satisfaction of all required conditions precedent, including receipt of regulatory approvals completed. Duyuru • Jun 13
Perrigo Company plc Appoints Todd Penegor as Member of Board and to Serve on Audit Committee, Effective June 21, 2024 On June 7, 2024, the Board of Directors of Perrigo Company plc appointed Todd Penegor to serve as a member of the Company’s board of directors, to be effective June 21, 2024. Mr. Penegor will also serve on the Audit Committee of the Board. Mr. Penegor brings substantial experience as both a Chief Executive Officer and Chief Financial Officer of large companies. He most recently served as Chief Executive Officer for The Wendy’s Company, from 2016 to 2024, where he also previously served as Chief Financial Officer from 2013 to 2015. Prior to this, Mr. Penegor worked at Kellogg Company, a global leader in food products, from 2000 to 2013 where he held several key leadership positions in finance and executive roles. Before joining Kellogg, Mr. Penegor worked for 12 years at Ford Motor Company in various positions, including strategy, mergers and acquisitions, the controller’s office and treasury. Duyuru • May 30
Perrigo Company plc Announces Executive Changes Between May 21 and May 27, 2024, Kyle L. Hanson and Perrigo Company plc agreed to the following. Effective May 30, 2024, Ms. Hanson will step down from her positions as Executive Vice President (“EVP”), General Counsel and Corporate Secretary of the Company and relevant affiliates. Ms. Hanson will continue as Special Counsel to the CEO, the Board and Interim General Counsel for Strategic Litigation through September 15, 2024, with a primary focus on the Company’s ongoing securities litigation and related matters, after which time she will shift to an advisory role to provide transition services through December 31, 2024. The Company announced the appointment of Todd Kingma as Interim EVP, General Counsel and Corporate Secretary, effective May 30, 2024. Mr. Kingma retired from Perrigo in August 2022 after 19 years with the Company and has agreed to serve in the Interim role while the Company seeks a successor to Ms. Hanson. Upcoming Dividend • May 24
Upcoming dividend of US$0.28 per share Eligible shareholders must have bought the stock before 31 May 2024. Payment date: 18 June 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 3.9%. Lower than top quartile of British dividend payers (5.7%). Higher than average of industry peers (2.3%). New Risk • May 08
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 1.1x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Dividend is not well covered by earnings (dividend per share is over 138x earnings per share). Large one-off items impacting financial results. Reported Earnings • May 08
First quarter 2024 earnings released: EPS: US$0.03 (vs US$0.008 loss in 1Q 2023) First quarter 2024 results: EPS: US$0.03 (up from US$0.008 loss in 1Q 2023). Revenue: US$1.08b (down 8.4% from 1Q 2023). Net income: US$4.10m (up US$5.20m from 1Q 2023). Profit margin: 0.4% (up from net loss in 1Q 2023). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Declared Dividend • May 06
Fourth quarter dividend of US$0.28 announced Shareholders will receive a dividend of US$0.28. Ex-date: 31st May 2024 Payment date: 18th June 2024 Dividend yield will be 3.3%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is well covered by cash flows (46% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Duyuru • May 01
Perrigo Company plc Announces Quarterly Dividend, Payable on June 18, 2024 Perrigo Company plc announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on June 18, 2024, to shareholders of record on May 31, 2024. Duyuru • Apr 26
Esteve Healthcare S.L. agreed to acquire HRA Pharma Rare Diseases America, LLC from Perrigo Company plc (NYSE:PRGO) for approximately €280 million. Esteve Healthcare S.L. agreed to acquire HRA Pharma Rare Diseases America, LLC from Perrigo Company plc (NYSE:PRGO) for approximately €280 million on April 25, 2024. The transaction is subject to the satisfaction of the HRA Works Council consultation and customary closing conditions, including receipt of regulatory approvals and is expected to close during the third quarter of 2024. Morgan Stanley & Co. LLC acted as a financial advisor and Wachtell, Lipton, Rosen & Katz LLP acted as a legal advisor to Perrigo Company plc. Perella Weinberg Partners acted as a financial advisor and Clifford Chance S.L.P. acted as a legal advisor to Esteve Healthcare S.L. Duyuru • Apr 24
Perrigo Company plc to Report Q1, 2024 Results on May 07, 2024 Perrigo Company plc announced that they will report Q1, 2024 results on May 07, 2024 Duyuru • Mar 24
Perrigo Company plc, Annual General Meeting, May 02, 2024 Perrigo Company plc, Annual General Meeting, May 02, 2024, at 10:00 Coordinated Universal Time. Location: Sir John Rogerson's Quay, Grand Canal Dock Dublin 2 Ireland Agenda: To elect, by separate resolutions, ten director nominees to serve until the 2025 Annual General Meeting of Shareholders; to ratify, in a non-binding advisory vote, the appointment of Ernst & Young LLP as the Company's independent auditor, and authorize, in a binding vote, the Board of Directors, acting through the Audit Committee, to fix the remuneration of the auditor; to provide advisory approval of the Company's executive compensation; to renew the Board's authority to issue shares under Irish law; to renew the Board's authority to opt-out of statutory pre-emption rights under Irish law; and to transact any other business that may properly come before the meeting. Duyuru • Mar 09
Perrigo Company plc Announces Erica L. Mann Not to Stand for Re-Election to its Board of Directors On March 2, 2024, Erica L. Mann, an independent member of the Perrigo Company plc (the “Company”) Board of Directors, advised Perrigo’s Nominating & Governance Committee that she will not stand for re-election to its Board of Directors at the Company’s annual general meeting of shareholders in 2024 and intends to retire from its Board at that time. Ms. Mann, 65, has been a member of the Board since 2019 and currently serves on its Talent & Compensation Committee. Ms. Mann’s decision to retire is not the result of any disagreement with the Company, and she will continue in her role as director until the 2024 annual general meeting. Declared Dividend • Mar 04
Fourth quarter dividend increased to US$0.28 Dividend of US$0.28 is 1.1% higher than last year. Ex-date: 7th March 2024 Payment date: 26th March 2024 Dividend yield will be 4.1%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is well covered by cash flows (46% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Reported Earnings • Feb 29
Full year 2023 earnings released: US$0.033 loss per share (vs US$0.97 loss in FY 2022) Full year 2023 results: US$0.033 loss per share (improved from US$0.97 loss in FY 2022). Revenue: US$4.66b (up 4.6% from FY 2022). Net loss: US$4.40m (loss narrowed 97% from FY 2022). Revenue is forecast to grow 3.0% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Duyuru • Feb 27
Perrigo Company plc Increases its Quarterly Dividend, Payable on March 26, 2024 Perrigo Company plc announced that its Board of Directors has approved a 1% increase in the company's quarterly dividend to $0.276 per share, or $1.10 per share on an annual basis, up from $0.273 per share. This marks the 21st consecutive year Perrigo has increased its dividend. The cash dividend is payable on March 26, 2024, to shareholders of record on March 8, 2024. Duyuru • Feb 14
Perrigo Company plc to Report Q4, 2023 Results on Feb 27, 2024 Perrigo Company plc announced that they will report Q4, 2023 results on Feb 27, 2024 Upcoming Dividend • Nov 23
Upcoming dividend of US$0.27 per share at 3.6% yield Eligible shareholders must have bought the stock before 30 November 2023. Payment date: 19 December 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 3.6%. Lower than top quartile of British dividend payers (6.2%). Higher than average of industry peers (2.7%). Duyuru • Nov 09
Perrigo Company plc Updates Earnings Guidance for the Fiscal 2023 Perrigo Company plc updated earnings guidance for the fiscal 2023. The company now expects reported net sales growth of 4.0% to 6.0% compared to the prior year, versus the previous range of 7.0% to 11.0%, organic net sales growth of 1.0% to 3.0% compared to the prior year, versus the previous range of 3.0% to 6.0%. Duyuru • Oct 25
Perrigo Company plc to Report Q3, 2023 Results on Nov 07, 2023 Perrigo Company plc announced that they will report Q3, 2023 results on Nov 07, 2023 Duyuru • Sep 12
Perrigo Company plc Announces Executive Changes On September 11, 2023, James Dillard III and Perrigo Company plc agreed to a mutual separation, such that Mr. Dillard will no longer serve as Executive Vice President (“EVP”) & President, Consumer Self-Care Americas of the Company and all relevant subsidiaries and affiliates effective the same day. Mr. Dillard will continue in an advisory capacity until September 30, 2023. On September 11, 2023, the Company announced the appointment of Catherine “Triona” Schmelter as EVP and President, Consumer Self-Care Americas and Global Portfolio Optimization effective immediately. Prior to joining Perrigo, Ms. Schmelter was most recently at Treehouse Foods, where she most recently served as the Chief Transformation Officer, responsible for growth acceleration and capability building initiatives. Duyuru • Aug 10
Perrigo Company plc Reaffirms Earnings Guidance for the Fiscal 2023 Perrigo Company plc reaffirms earnings guidance for the fiscal 2023. The company reaffirms its fiscal 2023 organic net sales and total net sales growth outlook range of 3.0%-6.0% and 7.0%-11.0%, respectively, versus the prior year. Duyuru • Jul 26
Perrigo Company plc to Report Q2, 2023 Results on Aug 08, 2023 Perrigo Company plc announced that they will report Q2, 2023 results on Aug 08, 2023 Duyuru • Jul 14
Perrigo Company plc Announces U.S. FDA Approval for Opill OTC Daily Oral Contraceptive Perrigo Company plc announced that the U.S. Food and Drug Administration (FDA) approved Opill(R), a progestin-only daily oral contraceptive, for over-the-counter (OTC) use for all ages. Opill is the first ever birth control pill available over the counter in the United States. Nearly 50 years of use and scientific evidence demonstrate that progestin-only pills such as Opill are effective at preventing pregnancy and are safe for most women to use. OTC oral contraception has support from major medical organizations including the American College of Obstetricians and Gynecologists, the American Medical Association, the Society for Adolescent Health and Medicine and the American Academy of Family Physicians. Of the 6 million pregnancies in the U.S. each year, 45% are unintended. Nearly one-third of adult U.S. women who have ever tried to obtain a prescription or refill for a contraceptive pill, patch or ring reported difficulties doing so. Removing the prescription requirement for Opill improves access to a contraceptive method that is effective and well tolerated for all ages of women and people who can get pregnant. In May 2023, the FDA's Nonprescription Drugs Advisory Committee (NDAC) and the Obstetrics, Reproductive, and Urologic Drug Advisory Committee (ORUDAC) voted unanimously 17 to 0, with no abstentions, that the benefits of making Opill available for OTC use, outweigh the risks. 
